Meeting
2015 ASCO Annual Meeting
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
Authors
Timothy Jay Price
Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia
Timothy Jay Price , Marc Peeters , Tae Won Kim , Jin Li , Stefano Cascinu , Paul Ruff , Attili Venkatasatya Suresh , Anne L. Thomas , Sergei Tjulandin , Kathy Zhang , Roger Sidhu , Swaminathan Murugappan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01001377
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3586)
DOI
10.1200/jco.2015.33.15_suppl.3586
Abstract #
3586
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
First Author: Kaori Hayashi
Poster
2017 Gastrointestinal Cancers Symposium
Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.
First Author: Rachel Lee Delahunty